Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation.
Chromophobe renal cell carcinoma
Immune checkpoint inhibitor
Sarcomatoid differentiation
Journal
International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
11
03
2022
accepted:
14
06
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
4
10
2022
Statut:
epublish
Résumé
Renal cell carcinoma (RCC) is the most predominant type of kidney cancer in adults and comprises several histological subtypes. Among them, the chromophobe RCC (ChRCC) with sarcomatoid differentiation is a rare subtype, and its therapeutic strategy remains unclear. Hence, to provide more information on effective therapeutic strategies against ChRCC, we report two cases of ChRCC with sarcomatoid differentiation treated with nivolumab monotherapy or ipilimumab-nivolumab combination therapy. One patient was treated with nivolumab monotherapy after the failure of sunitinib, while the other was treated with ipilimumab-nivolumab combination therapy as a first-line option. The therapeutic strategies adopted in both cases were effective, but the patients experienced immune-related adverse events such as interstitial nephritis and colitis. Thus, our report indicates that immune checkpoint therapy is effective for ChRCCs with sarcomatoid differentiation.
Identifiants
pubmed: 36186227
doi: 10.1007/s13691-022-00561-y
pii: 561
pmc: PMC9522941
doi:
Types de publication
Case Reports
Langues
eng
Pagination
286-291Informations de copyright
© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2022.
Déclaration de conflit d'intérêts
Conflict of interestJun Teishima has received lecture fees from Ono Pharmaceutical Co., Ltd and Bristol Myers Squibb™.
Références
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
Clin Genitourin Cancer. 2019 Oct;17(5):373-379.e4
pubmed: 31326335
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Int J Urol. 2019 Sep;26(9):868-877
pubmed: 31183903
Cancers (Basel). 2020 Feb 17;12(2):
pubmed: 32079343
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
J Urol. 2011 Jan;185(1):60-6
pubmed: 21074201
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Oncologist. 2020 Mar;25(3):252-258
pubmed: 32162795
Urol Oncol. 2018 Jul;36(7):339.e9-339.e15
pubmed: 29773493
J Immunother Cancer. 2018 Jan 29;6(1):9
pubmed: 29378660
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35210307
Lancet Oncol. 2016 Mar;17(3):378-388
pubmed: 26794930
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
Med Oncol. 2016 Nov;33(11):120
pubmed: 27696122
Clin Genitourin Cancer. 2019 Jun;17(3):e678-e688
pubmed: 31036466
Urol Oncol. 2021 Nov;39(11):790.e17-790.e23
pubmed: 34301458
Am J Surg Pathol. 2004 Apr;28(4):435-41
pubmed: 15087662
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Oncologist. 2016 Oct;21(10):1212-1217
pubmed: 27382030